Small E J, Dawson N A, Kantoff P W, Vogelzang N J
University of California, San Francisco, School of Medicine, USA.
Semin Oncol. 1996 Dec;23(6 Suppl 14):28-31.
The approach to treatment for advanced prostate cancer patients who have failed to respond to therapy with androgen deprivation has undergone a significant and fundamental transformation over the last 3 years, beginning with the description of the flutamide-withdrawal syndrome in 1993. This was the same year that the Cancer and Leukemia Group B Prostate Cancer Committee was created. This committee has been studying the following two important areas in advanced prostate cancer the optimal treatment and biology of androgen-independent, yet hormonally sensitive, prostate cancer; and the optimal treatment for patients with truly hormone-refractory disease. Important biologic and quality of life correlative trials will complement the clinical information gained, with the goal of providing further insight into the extremely complex biological processes involved.
对于那些对雄激素剥夺治疗无反应的晚期前列腺癌患者，其治疗方法在过去3年中经历了重大而根本的转变，这始于1993年对氟他胺撤药综合征的描述。同年，癌症与白血病B组前列腺癌委员会成立。该委员会一直在研究晚期前列腺癌的以下两个重要领域：雄激素非依赖性但激素敏感的前列腺癌的最佳治疗方法和生物学特性；以及真正激素难治性疾病患者的最佳治疗方法。重要的生物学和生活质量相关性试验将补充所获得的临床信息，目的是进一步深入了解所涉及的极其复杂的生物学过程。
